Fred Alger Management’s Protagonist Therapeutics PTGX Stock Holding History

Fred Alger Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$938K	Buy	+7,650	New	+$799K	﹤0.01%	367
2025 Q2	–	Sell	-7,477	Closed	-$362K	–	470
2025 Q1	$362K	Buy	+7,477	New	+$313K	﹤0.01%	375
2023 Q3	–	Sell	-21,719	Closed	-$600K	–	518
2023 Q2	$600K	Buy	21,719 +10,114	+87%	+$253K	﹤0.01%	391
2023 Q1	$267K	Buy	+11,605	New	+$195K	﹤0.01%	418

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fred Alger Management's PTGX Position: Q2 2026 in Review

Fred Alger Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 7,650 shares worth $938K. The stake represents ﹤0.01% of the portfolio and ranks #367 among its holdings. This is a return to the name: Fred Alger Management previously reported a position in PTGX as recently as Q1 2025.

Fred Alger Management first reported a position in PTGX in Q1 2023 and has held it in 4 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Fred Alger Management held 7,650 shares of Protagonist Therapeutics worth $938K as of Q2 2026.
Protagonist Therapeutics was a new Fred Alger Management position in Q2 2026.
Protagonist Therapeutics made up ﹤0.01% of Fred Alger Management's portfolio in Q2 2026, its #367 holding.
Fred Alger Management first reported a position in Protagonist Therapeutics in Q1 2023 and has held it in 4 quarters since.
344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.